184 related articles for article (PubMed ID: 36282437)
1. Diagnostic utility of immunohistochemistry in concordance with mRNA analysis of PRAME in the stratification of high-risk uveal melanoma patients.
Kumar N; Singh MK; Singh L; Lomi N; Meel R; Pushker N; Sen S; Kashyap S
Hum Cell; 2023 Jan; 36(1):342-352. PubMed ID: 36282437
[TBL] [Abstract][Full Text] [Related]
2. Prognostic Value of BAP1 and Preferentially Expressed Antigen in Melanoma (PRAME) Immunohistochemistry in Uveal Melanomas.
Han LM; Lee KW; Uludag G; Seider MI; Afshar AR; Bloomer MM; Pekmezci M
Mod Pathol; 2023 Apr; 36(4):100081. PubMed ID: 36788079
[TBL] [Abstract][Full Text] [Related]
3. PRAME as an Independent Biomarker for Metastasis in Uveal Melanoma.
Field MG; Decatur CL; Kurtenbach S; Gezgin G; van der Velden PA; Jager MJ; Kozak KN; Harbour JW
Clin Cancer Res; 2016 Mar; 22(5):1234-42. PubMed ID: 26933176
[TBL] [Abstract][Full Text] [Related]
4. Relationship between clinical features, GEP class, and PRAME expression in uveal melanoma.
Schefler AC; Koca E; Bernicker EH; Correa ZM
Graefes Arch Clin Exp Ophthalmol; 2019 Jul; 257(7):1541-1545. PubMed ID: 31065847
[TBL] [Abstract][Full Text] [Related]
5. Characterisation of the protein expression of the emerging immunotherapy targets VISTA, LAG-3 and PRAME in primary uveal melanoma: insights from a southern French patient cohort.
Lamas NJ; Lassalle S; Martel A; Nahon-Estève S; Macocco A; Zahaf K; Lalvee S; Fayada J; Lespinet-Fabre V; Bordone O; Pedeutour F; Baillif S; Hofman P
Pathology; 2023 Dec; 55(7):929-944. PubMed ID: 37863710
[TBL] [Abstract][Full Text] [Related]
6. PRAME as a Potential Target for Immunotherapy in Metastatic Uveal Melanoma.
Gezgin G; Luk SJ; Cao J; Dogrusöz M; van der Steen DM; Hagedoorn RS; Krijgsman D; van der Velden PA; Field MG; Luyten GPM; Szuhai K; Harbour JW; Jordanova ES; Heemskerk MHM; Jager MJ
JAMA Ophthalmol; 2017 Jun; 135(6):541-549. PubMed ID: 28448663
[TBL] [Abstract][Full Text] [Related]
7. Immunohistochemical expression of PRAME is a marker of poor prognosis in uveal melanoma: A clinico-pathologic and immunohistochemical study on a series of 85 cases.
Broggi G; Failla M; Russo A; Longo A; Palicelli A; Zanelli M; Lombardo C; Loreto C; Merolla F; Di Crescenzo RM; Ilardi G; Varricchio S; Staibano S; Caltabiano R
Pathol Res Pract; 2023 Jul; 247():154543. PubMed ID: 37210771
[TBL] [Abstract][Full Text] [Related]
8. Ki67 is a better marker than PRAME in risk stratification of BAP1-positive and BAP1-loss uveal melanomas.
Donizy P; Spytek M; Krzyziński M; Kotowski K; Markiewicz A; Romanowska-Dixon B; Biecek P; Hoang MP
Br J Ophthalmol; 2023 Sep; ():. PubMed ID: 37734766
[TBL] [Abstract][Full Text] [Related]
9. Gene Expression Profiling and PRAME Status Versus Tumor-Node-Metastasis Staging for Prognostication in Uveal Melanoma.
Cai L; Paez-Escamilla M; Walter SD; Tarlan B; Decatur CL; Perez BM; Harbour JW
Am J Ophthalmol; 2018 Nov; 195():154-160. PubMed ID: 30092184
[TBL] [Abstract][Full Text] [Related]
10. Preferentially Expressed Antigen in Melanoma Immunohistochemistry Labeling in Uveal Melanomas.
Ahmadian SS; Dryden IJ; Naranjo A; Toland A; Cayrol RA; Born DE; Egbert PS; Brown RA; Mruthyunjaya P; Lin JH
Ocul Oncol Pathol; 2022 Jun; 8(2):133-140. PubMed ID: 35959159
[TBL] [Abstract][Full Text] [Related]
11. Epigenetic reprogramming and aberrant expression of PRAME are associated with increased metastatic risk in Class 1 and Class 2 uveal melanomas.
Field MG; Durante MA; Decatur CL; Tarlan B; Oelschlager KM; Stone JF; Kuznetsov J; Bowcock AM; Kurtenbach S; Harbour JW
Oncotarget; 2016 Sep; 7(37):59209-59219. PubMed ID: 27486988
[TBL] [Abstract][Full Text] [Related]
12. PRAME Expression: A Target for Cancer Immunotherapy and a Prognostic Factor in Uveal Melanoma.
Gelmi MC; Gezgin G; van der Velden PA; Luyten GPM; Luk SJ; Heemskerk MHM; Jager MJ
Invest Ophthalmol Vis Sci; 2023 Dec; 64(15):36. PubMed ID: 38149971
[TBL] [Abstract][Full Text] [Related]
13. Differential expression of p52 and RelB proteins in the metastatic and non-metastatic groups of uveal melanoma with patient outcome.
Singh MK; Singh L; Chosdol K; Pushker N; Saini N; Meel R; Bakhshi S; Sen S; Kashyap S
J Cancer Res Clin Oncol; 2019 Dec; 145(12):2969-2982. PubMed ID: 31612319
[TBL] [Abstract][Full Text] [Related]
14. Patterns of BAP1 protein expression provide insights into prognostic significance and the biology of uveal melanoma.
Farquhar N; Thornton S; Coupland SE; Coulson JM; Sacco JJ; Krishna Y; Heimann H; Taktak A; Cebulla CM; Abdel-Rahman MH; Kalirai H
J Pathol Clin Res; 2018 Jan; 4(1):26-38. PubMed ID: 29416875
[TBL] [Abstract][Full Text] [Related]
15. Prognostic Value of BAP1 Protein Expression in Uveal Melanoma.
Kennedy S; Owens S; Ivers L; Hegarty C; O'Neill V; Berenguer-Pina JJ; Horgan N; Crown J; Walsh N
Am J Surg Pathol; 2024 Mar; 48(3):329-336. PubMed ID: 38238977
[TBL] [Abstract][Full Text] [Related]
16. Association of Ultrasound Features in Uveal Melanoma With Metastatic Risk as Defined by Preferentially Expressed Antigen in Melanoma Status.
Rusakevich AM; Schefler AC; Zhou B; Brown A; Robe C; Bretana ME
Ophthalmic Surg Lasers Imaging Retina; 2022 Jul; 53(7):374-378. PubMed ID: 35858230
[TBL] [Abstract][Full Text] [Related]
17. Cancer-testis antigen expression in synovial sarcoma: NY-ESO-1, PRAME, MAGEA4, and MAGEA1.
Iura K; Maekawa A; Kohashi K; Ishii T; Bekki H; Otsuka H; Yamada Y; Yamamoto H; Harimaya K; Iwamoto Y; Oda Y
Hum Pathol; 2017 Mar; 61():130-139. PubMed ID: 27993576
[TBL] [Abstract][Full Text] [Related]
18. Clinicopathological Characteristics and Prognosis for Survival after Enucleation of Uveal Melanoma in Chinese Patients: Long-term Follow-up.
Yue H; Qian J; Yuan Y; Zhang R; Bi Y; Meng F; Xuan Y
Curr Eye Res; 2017 May; 42(5):759-765. PubMed ID: 27911584
[TBL] [Abstract][Full Text] [Related]
19. Lack of BAP1 protein expression in uveal melanoma is associated with increased metastatic risk and has utility in routine prognostic testing.
Kalirai H; Dodson A; Faqir S; Damato BE; Coupland SE
Br J Cancer; 2014 Sep; 111(7):1373-80. PubMed ID: 25058347
[TBL] [Abstract][Full Text] [Related]
20. Uveal Melanoma Nuclear BRCA1-Associated Protein-1 Immunoreactivity Is an Indicator of Metastasis.
Szalai E; Wells JR; Ward L; Grossniklaus HE
Ophthalmology; 2018 Feb; 125(2):203-209. PubMed ID: 28823399
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
